http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 03 Feb 2026 19:01:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Feb. 3, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended <chron>December 31, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2025+Annual+Results/25940983.html Tue, 03 Feb 2026 19:01:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html <div class="xn-content"> <p><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location>, <span class="legendSpanClass"><chron>Jan. 18, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce^[1].</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Acquires+Common+Stock+in+Spruce+Biosciences%2C+Deepening+Strategic+Collaboration/25861820.html Sun, 18 Jan 2026 19:02:00 -0500 02142 2142 6XY O.34279193 O.37894223 SPRB http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 28, 2025</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with <span>Yantai Lannacheng Biotechnology Co., Ltd.</span> ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html Sun, 28 Dec 2025 20:58:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 28, 2025</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with <span>Yantai Lannacheng Biotechnology Co., Ltd.</span> ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html Sun, 28 Dec 2025 20:58:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 28, 2025</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with <span>Yantai Lannacheng Biotechnology Co., Ltd.</span> ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html Sun, 28 Dec 2025 20:58:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 28, 2025</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with <span>Yantai Lannacheng Biotechnology Co., Ltd.</span> ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html Sun, 28 Dec 2025 20:58:00 -0500 02142 2142 6XY O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 28, 2025</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with <span>Yantai Lannacheng Biotechnology Co., Ltd.</span> ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Enters+into+Long-Term+Strategic+Collaboration+with+Lannacheng+to+Advance+Next-Generation+Radionuclide+Drug+Conjugates/25780364.html Sun, 28 Dec 2025 20:58:00 -0500 02142 2142 6XY O.34279193